For more information contact:
Mattson Communications, Inc.
Kathy Mattson
312-988-9352
kathy@mattsonpr.com

TransMolecular, Inc.
Alyssa Vanderpool
617-995-3050 ext. 302
vanderpool@transmolecular.com

TransMolecular Appoints Dr. Alison M. O'Neill As Vice President of Medical Affairs

Cambridge, Mass. – April 18, 2006 – TransMolecular, Inc., a biotechnology company focused on cancer drug development, today announced the appointment of Alison M. O'Neill, M.D. to the position of Vice President of Medical Affairs. Dr. O'Neill comes to TransMolecular from Pappas Center for Neuro-Oncology at Massachusetts General Hospital, where she was Clinical Director of Neuro-Oncology and Chairman of the Brain Tumor Protocol Review Committee for the past four years.

Dr. O'Neill will be responsible for overseeing all medical affairs activities for TransMolecular and will serve as a member of the company's executive management team. In these capacities, Dr. O'Neill will provide leadership and scientific support for the company's cancer therapy development areas, including its ongoing Phase II trial for adult patients with recurrent high-grade glioma and additional Phase I trials currently in progress or planned.

"We are very fortunate to have Alison join us to guide the direction of our medical affairs," said E. Michael Egan, President and CEO of TransMolecular. "Her extensive background and dedication to understanding and improving the treatment of patients with neuro-oncology diseases are a perfect fit with our vision to develop new products designed to diagnose and treat these and other forms of cancer."

- more -

"I am very excited to be joining TransMolecular at this time," said Dr. O'Neill. "The company is very attractive because its drug development pipeline is so unique in the industry, and its executive management team is first rate. I look forward to developing TransMolecular's medical affairs activities to better share emerging scientific and clinical data from our drug development efforts with our clinical investigators and collaborators."

A licensed physician and specialist in neuro-oncology, Dr. O'Neill also has been an Assistant Professor of Neurology at Harvard Medical School for the last four years. She completed a fellowship in the Neuro-Oncology Unit at Memorial Sloan-Kettering Cancer Center, a residency in the Department of Neurology at University of Michigan Hospitals in Ann Arbor, Michigan and an internship in the Department of Internal Medicine at the University of Chicago Hospitals.

Prior to her work with Massachusetts General Hospital, Dr. O'Neill served as the Clinical Director of Brain Tumor Treatment and Research at the University of Alabama at Birmingham (UAB) and was the Director of the Neurology Residency Training Program at UAB. While at UAB, Dr. O'Neill was involved with TransMolecular's first clinical study of Chlorotoxin, or TM-601, in humans.

Dr. O'Neill has earned many academic and medical staff appointments. She has served as the principal investigator in several research studies of cancer therapies in patients with newly diagnosed glioblastoma multiforme and recurrent high-grade glioma. Dr. O'Neill also has published numerous abstracts and journal articles. She earned her M.D. at the Pritzker School of Medicine at the University of Chicago and holds a B.A. in biological sciences also from the University of Chicago. She is board certified by the American Board of Psychiatry and Neurology and has received certification in imaging interpretation from the American Society of Neuroimaging (MRI and CT).

About TransMolecular, Inc.

TransMolecular, Inc. is a privately held, venture capital backed biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat cancer diseases having inadequate pharmaceutical alternatives. Research on TransMolecular's product pipeline based on a small peptide derived from scorpion venom that is expected to be useful in treating a wide variety of cancers is ongoing. More information can be found at www.transmolecular.com.

####